More important acronym: BTD. Truly clinically meaningful improvement would likely qualify 2-73 for Breakthrough Designation in PDD, which is a serious and under-treated condition, and would expedite testing and approval review.
We would prepare a BTD submission (after adequately processing the trial data) and apply for it, and would hear back from the FDA within 60 days.
Let's see what the results are tomorrow, and if the company makes any mention of BTD.